Biotech grants in the United Kingdom

Between cycles

Supports EIC beneficiaries' participation in major trade fairs across the EU, MENA and the US.

Between cycles

Funds early-stage deep tech startups developing solutions at TRL 4-5 in collaboration with industry partners through a 4-month co-creation programme.

Between cycles

Funds a €15M project that turns microbiome signals into a test for spotting cancer risk years ahead of any symptoms.

Between cycles

Funds a €5M programme that pairs EU and Associated Country research institutions with Ukrainian cancer centres for joint training and staff exchanges.

Between cycles

Funds up to four €8-9M grants for teams building AI-driven digital models of a patient's cancer to predict how it develops and guide personalised treatment.

Between cycles

Funds three pragmatic clinical trials, €7-8M each, testing existing cancer immunotherapies in real-world care for patients whose disease resists treatment.

Between cycles

Funds two €7M projects that map how antimicrobial resistance develops in soil and turn it into guidance for policymakers and land managers.

Between cycles

Runs themed competitions in which teams compete over several stages to solve one defined technical problem.

Between cycles

Supports early-stage German innovators through a pilot challenge route with mentoring and development funding.

Closed

Funds bottom-up research for breakthrough deep-tech, any field of science.

Closed

Supports European deep-tech ventures advancing laboratory research toward validated prototypes and near-market technologies.

Closed

Pays up to 25 small consortia EUR 200,000 each to test the commercial exploitation potential of results that already came out of earlier Horizon Europe or Horizon 2020 Cluster 4 projects.

Closed

Funds clinical trials of prophylactic vaccines against neglected tropical diseases such as schistosomiasis, leishmaniasis and leprosy in sub-Saharan Africa.

Closed

Pays deep-tech start-ups, SMEs and research organisations a €300,000 lump sum in Stage 1, then up to €2.5 million in Stage 2, to push high-risk breakthrough innovations that lack commercial uptake toward real-world, demand-tested deployment.

Closed

Funds early clinical trials of therapies built from the molecules cells secrete rather than the cells themselves, aiming for an off-the-shelf alternative to cell therapy.

Closed

Funds research into biomanufactured alternatives to imported natural rubber and fossil-based synthetic rubber for automotive, healthcare and industrial uses.

Closed

Funds research into bio-based, biodegradable delivery coatings for fertilisers that replace today's microplastic-shedding polymer coatings.

Closed

Funds a full-scale biorefinery that produces bio-based drop-in platform chemicals able to compete directly with their fossil-based equivalents.

Closed

Pays 200,000 euros to study bioengineering business ideas that use microgravity.

Closed

Funds biodiscovery projects that use AI and digital tools to find and sustainably produce new natural compounds from marine and freshwater organisms.

Closed

Funds companies discovering and scaling up bioactive natural compounds from land-based organisms for pharma, cosmetics, food and other markets.

Closed

Funds biotechnology and monitoring tools that remove persistent contaminants from marine, freshwater and groundwater systems.

Closed

Funds early-stage research teams developing climate-resilient crops and plant-based biomanufacturing of high-value nutrients.

Closed

Funds small, SME-majority consortia running an early-phase clinical trial to move a biotech therapy, from antibodies to RNA therapies, from the lab towards the market.